17
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      “Surfactants - compounds for inactivation of SARS-CoV-2 and other enveloped viruses“

      review-article
      a , b , b , c , d ,
      Current Opinion in Colloid & Interface Science
      Published by Elsevier Ltd.
      surfactant, virus inactivation, disinfection, enveloped viruses, lipid bilayers, AFM, atomic force microscopy, BVDV, Bovine Viral Diarrhea Virus, C12E8, dodecyloctaglycol, cac, critical aggregate concentration, cmc, critical micelle concentration, CPyC, cetylpyridinium chloride, DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine, Flu, influenza virus, HIV, human immunodeficiency virus, HSV, herpes simplex virus, ITC, isothermal titration calorimetry, Ld, liquid-disordered, Lo, liquid-ordered, p, packing parameter, PA, phosphatidic acid (anionic), PC, phosphatidylcholine (zwitterionic), PE, phosphatidylethanolamine (zwitterionic), PI, phosphatidylinositol (anionic), POPC, 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, PS, phosphatidylserine (anionic), QUAT, quaternary alkyl ammonium, RNP, ribonucleoprotein particle, SAXS, small-angle x-ray scattering, SDS, sodium dodecyl sulfate, TBP, tri-n-butyl phosphate, TEM, transmission electron microscopy

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We provide here a general view on the interactions of surfactants with viruses, with a particular emphasis on how such interactions can be controlled and employed, for inhibiting the infectivity of enveloped viruses, including coronaviruses. The aim is to provide to interested scientists from different fields, including chemistry, physics, biochemistry, and medicine, an overview over the basic properties of surfactants and (corona)viruses, which are relevant to understanding the interactions between the two. Various types of interactions between surfactant and virus are important, and they act on different components of a virus such as the lipid envelope, membrane (envelope) proteins and nucleo-capsid proteins. Accordingly, this cannot be a detailed account of all relevant aspects, but instead a summary that bridges between the different disciplines. We describe concepts and cover a selection of the relevant literature as an incentive for diving deeper into the relevant material. Our focus is on more recent developments around the COVID-19 pandemic caused by SARS-CoV-2, applications of surfactants against the virus, and on the potential future use of surfactants for pandemic relief. However, we also cover the most important aspects of the historical development of using surfactants in combatting virus infections. We conclude that surfactants are already playing very important roles in various directions of defence against viruses, either directly, as in disinfection, or as carrier components of drug delivery systems for prophylaxis or treatment. By designing tailor-made surfactants and, consequently, advanced formulations, one can expect a more and more effective use of surfactants, either directly as antiviral compounds or as part of more complex formulations.

          Related collections

          Most cited references158

          • Record: found
          • Abstract: found
          • Article: not found

          SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

          Summary The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Virological assessment of hospitalized patients with COVID-2019

            Coronavirus disease 2019 (COVID-19) is an acute infection of the respiratory tract that emerged in late 20191,2. Initial outbreaks in China involved 13.8% of cases with severe courses, and 6.1% of cases with critical courses3. This severe presentation may result from the virus using a virus receptor that is expressed predominantly in the lung2,4; the same receptor tropism is thought to have determined the pathogenicity-but also aided in the control-of severe acute respiratory syndrome (SARS) in 20035. However, there are reports of cases of COVID-19 in which the patient shows mild upper respiratory tract symptoms, which suggests the potential for pre- or oligosymptomatic transmission6-8. There is an urgent need for information on virus replication, immunity and infectivity in specific sites of the body. Here we report a detailed virological analysis of nine cases of COVID-19 that provides proof of active virus replication in tissues of the upper respiratory tract. Pharyngeal virus shedding was very high during the first week of symptoms, with a peak at 7.11 × 108 RNA copies per throat swab on day 4. Infectious virus was readily isolated from samples derived from the throat or lung, but not from stool samples-in spite of high concentrations of virus RNA. Blood and urine samples never yielded virus. Active replication in the throat was confirmed by the presence of viral replicative RNA intermediates in the throat samples. We consistently detected sequence-distinct virus populations in throat and lung samples from one patient, proving independent replication. The shedding of viral RNA from sputum outlasted the end of symptoms. Seroconversion occurred after 7 days in 50% of patients (and by day 14 in all patients), but was not followed by a rapid decline in viral load. COVID-19 can present as a mild illness of the upper respiratory tract. The confirmation of active virus replication in the upper respiratory tract has implications for the containment of COVID-19.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents

              Summary Currently, the emergence of a novel human coronavirus, SARS-CoV-2, has become a global health concern causing severe respiratory tract infections in humans. Human-to-human transmissions have been described with incubation times between 2-10 days, facilitating its spread via droplets, contaminated hands or surfaces. We therefore reviewed the literature on all available information about the persistence of human and veterinary coronaviruses on inanimate surfaces as well as inactivation strategies with biocidal agents used for chemical disinfection, e.g. in healthcare facilities. The analysis of 22 studies reveals that human coronaviruses such as Severe Acute Respiratory Syndrome (SARS) coronavirus, Middle East Respiratory Syndrome (MERS) coronavirus or endemic human coronaviruses (HCoV) can persist on inanimate surfaces like metal, glass or plastic for up to 9 days, but can be efficiently inactivated by surface disinfection procedures with 62–71% ethanol, 0.5% hydrogen peroxide or 0.1% sodium hypochlorite within 1 minute. Other biocidal agents such as 0.05–0.2% benzalkonium chloride or 0.02% chlorhexidine digluconate are less effective. As no specific therapies are available for SARS-CoV-2, early containment and prevention of further spread will be crucial to stop the ongoing outbreak and to control this novel infectious thread.
                Bookmark

                Author and article information

                Journal
                Curr Opin Colloid Interface Sci
                Curr Opin Colloid Interface Sci
                Current Opinion in Colloid & Interface Science
                Published by Elsevier Ltd.
                1359-0294
                1359-0294
                12 June 2021
                12 June 2021
                : 101479
                Affiliations
                [a ]Dept. of Chemical Engineering and the Russell Berrie Nanotechnolgy Inst. (RBNI), Technion-Israel Institute of Technology, Haifa, IL-3200003, Israel
                [b ]Institut für Virologie, Fachbereich Veterinärmedizin, Freie Universität Berlin, Robert von Ostertag-Straße 7-13, 14163 Berlin, Germany
                [c ]Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Sciences, City University of Hong Kong, Kowloon Tong, Hong Kong
                [d ]Stranski-Laboratorium für Physikalische und Theoretische Chemie, Institut für Chemie, Straße des 17. Juni 124, Sekr. TC7, Technische Universität Berlin, D-10623 Berlin, Germany
                Author notes
                []Corresponding author.
                Article
                S1359-0294(21)00063-7 101479
                10.1016/j.cocis.2021.101479
                8196227
                34149296
                5a12e4a9-e837-4a17-9a8f-e4e805c41c99
                © 2021 Published by Elsevier Ltd.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 11 March 2021
                : 31 May 2021
                : 2 June 2021
                Categories
                Article

                surfactant,virus inactivation,disinfection,enveloped viruses,lipid bilayers,afm, atomic force microscopy,bvdv, bovine viral diarrhea virus,c12e8, dodecyloctaglycol,cac, critical aggregate concentration,cmc, critical micelle concentration,cpyc, cetylpyridinium chloride,dspc, 1,2-distearoyl-sn-glycero-3-phosphocholine,flu, influenza virus,hiv, human immunodeficiency virus,hsv, herpes simplex virus,itc, isothermal titration calorimetry,ld, liquid-disordered,lo, liquid-ordered,p, packing parameter,pa, phosphatidic acid (anionic),pc, phosphatidylcholine (zwitterionic),pe, phosphatidylethanolamine (zwitterionic),pi, phosphatidylinositol (anionic),popc, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine,ps, phosphatidylserine (anionic),quat, quaternary alkyl ammonium,rnp, ribonucleoprotein particle,saxs, small-angle x-ray scattering,sds, sodium dodecyl sulfate,tbp, tri-n-butyl phosphate,tem, transmission electron microscopy

                Comments

                Comment on this article